Anti-fibrotic characteristics of Vγ9+ γδ T cells in systemic sclerosis

Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):23-29. Epub 2016 Feb 9.

Abstract

Objectives: γδ T cells of the Vγ9Vδ2 subtype secrete anti-fibrotic cytokines upon isopentenyl pyrophosphate (IPP) stimulation. In this study, we sought to compare IPP and Zoledronate, an up-regulator of IPP, effects on proliferation and cytokine secretion of Vγ9+ T cells from systemic sclerosis (SSc) patients and healthy controls (HCs). We also examined the effect of IPP-triggered peripheral blood mononuclear cells (PBMC) on fibroblast procolla- gen secretion.

Methods: PBMC from SSc patients and HCs were stimulated by increasing concentrations of Zoledronate, with or without IPP, and Vγ9+ T cell percentages were calculated using FACScan analysis. Subsequently, PBMC were cultured with IPP or toxic shock syndrome toxin-1 (TSST-1), and contents of the anti-fibrotic cytokines tumour necrosis factor (TNF)-α and interferon (IFN)-γ were measured by ELISA kits. Finally, supernatants of IPP-triggered Vγ9+ T cells from SSc patients were added to fibroblast cultures, and relative intensities of procollagen α1 chains were determined by densinometry.

Results: Higher concentrations of Zoledronate were required for maximal proliferation of Vγ9+ T cells in 9 SSc patients compared to 9 HCs, irrespective of exogenous IPP. When compared to stimulation by TSST-1, a non-Vγ9+ selective reagent, secretion of the anti-fibrotic cytokines TNF-α and IFN-γ in response to IPP was relatively diminished in SSc but not in HCs. Reduction of procollagen secretion by fibroblasts cultured with supernatants of IPP-stimulated PBMC was observed only in some SSc patients.

Conclusions: Activated Vγ9+ T cells could act as anti-fibrotic mediators in SSc, although decreased responsiveness to IPP may play a role in the pathological fibrosis of this disease.

MeSH terms

  • Case-Control Studies
  • Cell Proliferation
  • Cells, Cultured
  • Collagen Type I / metabolism
  • Diphosphonates / pharmacology
  • Dose-Response Relationship, Drug
  • Fibroblasts / immunology
  • Fibroblasts / metabolism
  • Fibrosis
  • Hemiterpenes / pharmacology
  • Humans
  • Imidazoles / pharmacology
  • Interferon-gamma / immunology
  • Interferon-gamma / metabolism
  • Lymphocyte Activation* / drug effects
  • Organophosphorus Compounds / pharmacology
  • Phenotype
  • Procollagen / metabolism
  • Receptors, Antigen, T-Cell, gamma-delta / immunology*
  • Receptors, Antigen, T-Cell, gamma-delta / metabolism
  • Scleroderma, Systemic / immunology*
  • Scleroderma, Systemic / metabolism
  • Scleroderma, Systemic / pathology
  • Signal Transduction
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / metabolism
  • Tumor Necrosis Factor-alpha / immunology
  • Tumor Necrosis Factor-alpha / metabolism
  • Zoledronic Acid

Substances

  • Collagen Type I
  • Diphosphonates
  • Hemiterpenes
  • IFNG protein, human
  • Imidazoles
  • Organophosphorus Compounds
  • Procollagen
  • Receptors, Antigen, T-Cell, gamma-delta
  • T-cell receptor Vgamma9, human
  • Tumor Necrosis Factor-alpha
  • isopentenyl pyrophosphate
  • Zoledronic Acid
  • Interferon-gamma